---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-26-000593"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2026-05-13T11:01:04+00:00"
generated_at: "2026-05-13T11:10:08.451849+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunic reports Q1 net loss $32.6M; cash $186.6M; Phase 3 MS data by end-2026

## Summary
- Net loss $32.6M ($1.08/share) vs $25.5M ($2.51/share) YoY; R&D expenses $25.6M.
- Closed $200M private placement (up to $400M) in Feb 2026; cash $186.6M funds into late 2027.
- Appointed Michael Panzara, M.D., as CMO; initiated CEO search with commercial neurology expertise.
- Phase 3 ENSURE RMS top-line data expected by end 2026; NDA submission planned mid-2027.
- Key European patent granted for vidofludimus calcium with potential exclusivity into 2043.

## SEC filing metadata
- accession: 0001193805-26-000593
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2026-05-13T11:01:04+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000593/0001193805-26-000593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000593/e665461_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-26-000593
- JSON: https://secwatch.observer/filing/0001193805-26-000593.json
- Plain text: https://secwatch.observer/filing/0001193805-26-000593.txt

## Key facts
- Earnings Releases
  IMMUNIC, INC. reported financial results for first quarter ended March 31, 2026.
  - Period: first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 13 2026, Immunic, Inc. (the “Company”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter ended March 31, 2026, and providing a corporate update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000593/0001193805-26-000593-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.